In terms of Ki-67 proliferation index, a key marker of tumor aggressiveness, patients in our study with a Ki-67 index of ≤20% showed promising PFS and overall survival (OS) (Ki-67 ≤20% vs. Ki-67 21%-55%: PFS: 25.3 vs. 11.4 months, respectively, p = 0.03; OS: 39.9 vs. 19.2 months, respectively, p = 0.07). This evidence concerns the gene MKI67 and neoplasm.